Insulet (NASDAQ:PODD) Sets New 1-Year High at $236.62

Insulet Co. (NASDAQ:PODD)’s stock price reached a new 52-week high during trading on Monday . The company traded as high as $236.62 and last traded at $233.96, with a volume of 24023 shares traded. The stock had previously closed at $233.87.

Analyst Ratings Changes

Several analysts have issued reports on the company. Barclays upped their price objective on Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a research note on Monday, August 12th. Redburn Atlantic assumed coverage on shares of Insulet in a research note on Thursday, May 30th. They set a “buy” rating and a $235.00 price objective on the stock. Piper Sandler lifted their target price on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research note on Tuesday. BTIG Research dropped their price target on Insulet from $270.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Finally, OTR Global reissued a “mixed” rating on shares of Insulet in a report on Monday, June 10th. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $229.21.

Insulet Stock Performance

The firm’s fifty day simple moving average is $199.93 and its 200 day simple moving average is $186.51. The company has a market capitalization of $16.51 billion, a price-to-earnings ratio of 71.38, a PEG ratio of 4.31 and a beta of 1.21. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing the consensus estimate of $0.56 by ($0.01). Insulet had a net margin of 21.11% and a return on equity of 30.73%. The firm had revenue of $488.50 million during the quarter, compared to analysts’ expectations of $488.00 million. During the same quarter last year, the company posted $0.38 EPS. The firm’s revenue was up 23.2% compared to the same quarter last year. On average, sell-side analysts forecast that Insulet Co. will post 3.04 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in Insulet by 1.1% in the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,265 shares of the medical instruments supplier’s stock valued at $1,264,000 after buying an additional 66 shares during the period. UMB Bank n.a. increased its position in Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 81 shares during the last quarter. Moody National Bank Trust Division raised its stake in shares of Insulet by 2.6% during the 1st quarter. Moody National Bank Trust Division now owns 3,439 shares of the medical instruments supplier’s stock worth $589,000 after purchasing an additional 87 shares in the last quarter. Motley Fool Asset Management LLC lifted its holdings in shares of Insulet by 7.1% during the 1st quarter. Motley Fool Asset Management LLC now owns 1,397 shares of the medical instruments supplier’s stock valued at $239,000 after buying an additional 93 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Insulet by 10.5% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,000 shares of the medical instruments supplier’s stock valued at $202,000 after buying an additional 95 shares during the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.